Characterization of Celecoxib β-Cyclodextrin Inclusion Complexes Using Solvent Evaporation Method

  • Henni Rosaini Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia
  • Novena Sandra Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia
  • Auzal Halim Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Abstract

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of pain and inflammation. Celecoxib is included in class II in the Biopharmaceutis ClassificationAsystem drug (BCS) which has low solubility and high permeability. This study aims to increase the solubility and dissolution rate of celecoxib by characterizing the inclusion complex of celecoxib β-cyclodextrin. Inclusion complexes were prepared by the solvent evaporation method using a water-soluble polymer, β-cyclodextrin. The inclusion complexes were prepared in a 1: 1 ratio between celecoxib and β-cyclodextrins. As a comparison, a physical mixture with the same composition was made. Powder mixtures of physics and inclusion complexes characterized by physicochemical properties include: FT-IR spectroscopy analysis, DSC analysis, assay and dissolution test. The dissolution test was determined by the paddle method. The results of characterization of the inclusion complex using FT-IR spectrophotometry showed a shift in the wave number as well as the physical interaction between celecoxib and β-cyclodextrin. The results of the DSC (Differential Scanning Calorimetry) decreased the enthalpy and melting point between celecoxib, the physical mixture and the inclusion complex. The dissolution test showed an increase in dissolution rate at 60 minutes, namely Celecoxib 55.03%, physical mixture 61.58% and inclusion complex 67.53%.


 

Keywords: celecoxib, β-cyclodextrin, inclusion complex, solvent evaporation, dissolution test

Downloads

Download data is not yet available.

Author Biographies

Henni Rosaini, Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Novena Sandra, Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Auzal Halim, Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

Department of Pharmaceutics, School of Pharmaceutical Sciences (STIFARM), Padang, West Sumatera 25147, Indonesia

References

1. Ansel, H. C. (2008). Pengantar bentuk sediaan farmasi. (Edisi 4). Penerjemah: F.Ibrahim. Jakarta: Universitas Indonesia Press.
2. Reintjes, T. (2011). Solubility enhancement with BASF pharma polymers solubilizer compendium. Germany: Pharma ingredients & services.
3. J. Fort. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J.Orthop,1999;(28):13–18.
4. Loftsson, T., & Brewster, M. E.Pharmaceutical applications of β-siklodekstrin, drug solubilization and stabilization. J Pharm Sci. 1996; 85(10):1017-1024.
5. Loftsson T, Jarho P, Masson M, Jarvinen T. Cylodextrin in Drug Delivery, Expert Opinion Drug Delivey, 2005; 2:335-351
6. Duchene, D. (2011). Cyclodextrin And Their Inclusion Complexes, In Bilensoy, E. Cyclodextrin In Pharmaceutics, Cosmetics and Biomedicine. John Wiley & Sons, Inc., New Jersey, Canada.
7. Patil, J. S., Kadam, D. V., Marapur, S. C., & Kamalapur, M. V. Inclusion Complex System ; A novel technique to improve the solubility and bioavailability of poorly soluble drugs. International Journal of Pharmaceutical Sciences Review and Reserch, 2010; 2, (2), 29-34.
8. Sahoo, S., Chakraborti, K,C., Misrha,C, S., Nanda, Nath., Upendra & Naik, S. FTIR and XRD Investigations Of Some Flouroquinolones. International Journal Of Pharmacy and Pharmacetical Sciences.2011; 3(3).
9. Liu, Y., Sun, C., Hao, Y., Jiang, T., Zheng., & Wang,S. Mechanism of dissolution enhancement and bioavaibility of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. Journal of pharmacy & pharmaceutical sciences,2008; 13(4):589.
10. Reddy, M.N., M., Rehana, T., Ramakrishna, S., Chowdary, K. P.R., &Diwan,P.V.β-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci,2004; 6(1).
11. Jouyban-Gharamaleki, V., Soleymani, J., Jouyban-Gharamaleki, K., Suleymanov, T. A., & Jouyban, A. Solubilization of celecoxib, lamotrigine and phenytoin using ethanol and a nonionic surfactant. Journal of Molecular Liquids, 2017; 243:715–719.
12. Dachriyanus. (2004). Analisis struktur sensyawa organik secara spektroskopi. Padang: Andalas Universitty Press.
13. Ginting, A., Sutri, I., & Jan, S. Penentuan Parameter Uji dan Ketidakpastian Pengukuran Kapasitas Panas Pada Differentian Scanning Calorimeter. J. Tek. Bhn. Nukl.2005; 1(1):1-57.
14. European Pharmacopoeia Commission. (2014) . European Directorate for the Quality of Medicines &Healthcare European Pharmacopoeia 8th Edition, Strasbourg : Council Of Europe .
15. Kementerian Kesehatan Republik Indonesia. (2014). Farmakope Indonesia. (Edisi V). Jakarta: Kementrian Kesehatan Republik Indonesia.
16. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009). Handbook of pharmaceutical exipients (6th ed). London: Pharmaceutical Press.
Statistics
485 Views | 188 Downloads
How to Cite
Rosaini, H., Sandra, N., & Halim, A. (2021). Characterization of Celecoxib β-Cyclodextrin Inclusion Complexes Using Solvent Evaporation Method. Asian Journal of Pharmaceutical Research and Development, 9(6), 41-47. https://doi.org/https://doi.org/10.22270/ajprd.v9i6.1037